摘要
目的分析2006—2008年南京地区22家医院医保甲类中成药的应用状况。方法对南京地区22家医院医保甲类中成药的用药品种、用药金额和用药频度等信息按年度进行统计分析。结果3年中甲类中成药实际使用品种数平均为87种,占医保目录的63.8%,用药金额占全部中成药用药金额的百分比平均为16.7%,并且呈逐年下降趋势。甲类中成药各大类用药金额排序几年保持相对稳定,其中心血管系统用药和其他类药物的用药金额的构成比较高,且增长幅度较大。用药金额前4位的是生脉、参麦、血栓通和复方丹参。用药频度排名显示,复方丹参、柴胡、麝香保心丸和银黄是临床选用频率较高的品种。用药金额最高的剂型是注射剂,而用药频度最高的剂型是胶囊剂。结论南京地区22家医院医保甲类中成药实际使用的品种数偏低,用药金额占中成药总金额的百分比较低,且逐年下降,剂型的使用较为合理,建议医保甲类中成药目录应适当调整并增加品种。
AIM To analyse the utilization of the type A Chinese patent drugs in the drug catalog of Medical Insurance used in 22 hospitals of Nanjing area during 2006--2008. METHODS The type A Chinese patent drugs in the drug catalog of Medical Insurance used in 22 hospitals of Nanjing area were analyzed statistically in respect to the variety, total consumption cost, and defined daily dose （DDDs） in each year. RESULTS The actual average varieties of the type A Chinese patent drugs in the drug catalog of Medical Insurance used in 3 years were 87 kinds and Medical Insurance was accounted for 63.8% of the catalog of Medical Insurance accounted for average 16.7% of all Chinese patent drugs and showed a downward trend year by year. Type A Chinese patent drugs in the drug catalog of Medical Insurance was sorted by the total consumption sum in 3 years as the major category, maintaining that relative stability, especially the cost coalition system of cardiovascular and other kind drugs in a relatively high proportion together with their large growth amplitude. Shengmai, Shenmai, Xueshuantong, and Fufangdanshen ranked as the four highest in the column of total consumption. The colum of DDDs indicated that Fufangdansheng, Chaihu, Shexiangbaoxin Pills, and Yinhuang were the most frequently used drugs in this area. The total consumption of injection ranked the toppest and the DDDs of capsule was also the highest. CONCLUSION The actual used varieties of the type A Chinese patent drugs in the drug catalog of Medical Insurance accounted and the total cost were a lower percentage of all Chinese patent drugs, showing a downward trend year by year. On the other hand the use of formulations is reasonable, therefore the catalogue of the type A Chinese patent drugs in the drug catalog of Medical Insurance should be adjusted more appropriately and increased the variety.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2009年第10期780-784,共5页
Chinese Journal of New Drugs and Clinical Remedies
关键词
中成药
药物利用
经济学
药学
南京地区
国家基本药物
医疗保脸
Chinese patent drugs
drug utilization
economics, pharmaceutical
Nanjing area
national essential drugs
Medical Insurance
